Lifecore goes private in $239m Warburg bid
This article was originally published in Clinica
Private equity firm Warburg Pincus is set to add Lifecore Biomedical to its growing list of medtech investments, after it had an offer of $239m accepted by the maker of dental and hyaluronan-based products.
You may also be interested in...
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer's COVID-19 vaccine in 2021 and beyond.
How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.